{"id":58427,"date":"2023-09-19T13:22:20","date_gmt":"2023-09-19T03:22:20","guid":{"rendered":"https:\/\/hudson.org.au?post_type=hdsn_news_post&#038;p=58427"},"modified":"2023-09-26T11:53:41","modified_gmt":"2023-09-26T01:53:41","slug":"cancer-drug-protects-against-excessive-inflammation-in-covid-infections","status":"publish","type":"hdsn_news_post","link":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/","title":{"rendered":"Cancer drug limits COVID inflammation"},"content":{"rendered":"\n<p class=\"has-medium-font-size\">A cancer drug could play an important role in limiting the damaging effects of lung disease inflammation in COVID-19 patients, thanks to new research at Hudson Institute.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"600\" height=\"600\" src=\"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg\" alt=\"Associate Professor Gantier's discovery that a cancer drug could be used to treat damaging inflammation in severe COVID-19 infections. \" class=\"wp-image-58441\" srcset=\"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg 600w, https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2-300x300.jpg 300w, https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2-150x150.jpg 150w, https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2-320x320.jpg 320w, https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2-400x400.jpg 400w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><figcaption class=\"wp-element-caption\"><em>Associate Professor Michael Gantier<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n<p>The body\u2019s inflammatory response to infection is important in controlling viruses, such as SARS-CoV-2, the virus causing COVID-19, but when inflammation gets out of control the effects can be lethal.<\/p>\n\n\n\n<p>With COVID infections on the increase in Europe and new sub-variants being detected, the need for new COVID treatments is as urgent as ever.<\/p>\n\n\n\n<p>Now a team led by <a href=\"https:\/\/hudson.org.au\/researcher-profile\/michael-gantier\/\">Associate Professor Michael Gantier <\/a>has established that idronoxil, which was originally designed to treat cancers, could reduce the inflammation that occurs in response to COVID-19.<\/p>\n\n\n\n<p>The research is published in the prestigious journal, <em><a href=\"https:\/\/www.nature.com\/articles\/s41467-023-41381-9\" target=\"_blank\" rel=\"noreferrer noopener\">Nature Communications<\/a><\/em>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cancer-drug-targets-covid-s-inflammatory-pathway\">Cancer drug targets COVID&#8217;s inflammatory pathway<\/h2>\n\n\n\n<p>\u201cEarly in the COVID-19 pandemic we realised that uncontrolled inflammation was one of the major life-threatening aspects of the infection, but we didn\u2019t know exactly how this inflammation occurred,\u201d A\/Prof Gantier said.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWhile fighting the infection caused by SARS-CoV-2, the immune system can sometimes go in overdrive &#8211; i.e. when the off-switch does not work.&#8221; A\/Prof Michael Gantier<\/p>\n<\/blockquote>\n\n\n\n<p>\u201cThe problem is that blocking the immune response too early can help the virus better replicate and do more damage.<\/p>\n\n\n\n<p>\u201cWe\u2019ve now shown that therapeutic targeting of a single protein activated by several inflammatory pathways can help limit the bad inflammation, without increasing viral replication in the lung,\u201d he said.<\/p>\n\n\n\n<p>\u201cThis led us to discover that idronoxil administered three days after infection could reduce the inflammation resulting from SARS-CoV-2 infection in a pre-clinical model of the severe disease.\u201d<\/p>\n\n\n\n<p>\u201cIn other words, we can let the body\u2019s inflammatory response go to work without going too far \u2013 we\u2019ve restored the off-switch.\u201d<\/p>\n\n\n\n<p>This preclinical work, with PhD student Tomalika Ullah, was conducted in parallel with an early clinical trial on moderate SARS-CoV-2 patients in 2021, which demonstrated that idronoxil was safe in this disease context.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-potential-to-treat-emerging-viruses\"><strong>Potential to treat emerging viruses<\/strong><\/h2>\n\n\n\n<p>A\/Prof Gantier believes idronoxil or its potential derivatives could be used to help treat viral induced lung hyperinflammation driven by emerging viruses \u2013 in other words, they could be the remedies that were so desperately needed during the COVID pandemic.<\/p>\n\n\n\n<p>As COVID-19 illustrated, our hospitals were ill-prepared to fight an influx of patients with respiratory distress, and more drugs are clearly needed to prevent this from happening again.<\/p>\n\n\n\n<p>A\/Prof Gantier and his team of academic and industry collaborators are currently developing idronoxil derivatives with enhanced anti-inflammatory activities, leveraging $1.45M funding support from the Victorian Government through the <a href=\"https:\/\/www.health.vic.gov.au\/medical-research\/covid-19-research\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 Treatments Medical Research Fund<\/a>.<\/p>\n\n\n\n<p>Acting Minister for Health Gabrielle Williams said this project was testament to Victoria being home to a world-class medical research community.<\/p>\n\n\n\n<p>\u201cWe\u2019re thrilled that through our various grants programs we can support some of the state\u2019s brightest minds to make life-changing scientific breakthroughs, like this one, so we can keep improving health outcomes for people not just here in Victoria but around the world,\u201d said Acting Minister Williams.<\/p>\n\n\n\n<p>Collaborators on this project include <a href=\"https:\/\/www.monash.edu\/discovery-institute\/de-nardo-lab\/home\" target=\"_blank\" rel=\"noreferrer noopener\">Monash University<\/a>, <a href=\"https:\/\/www.centenary.org.au\/research\/programs\/centenary-uts-centre-for-inflammation\/\" target=\"_blank\" rel=\"noreferrer noopener\">UTS and Centenary Institute<\/a>, ANU, St. Vincent\u2019s Institute of Medical Research, UNSW, University of Adelaide, Francis Crick Institute and <a href=\"https:\/\/www.noxopharm.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Noxopharm Limited<\/a>.<\/p>\n\n\n\n<p>&nbsp;<\/p>\n\n\n\n            <div class=\"inline-block-disease-snackbar bg-blue-100 border-l-4 border-pink-500 my-5 sm:my-8\">\n                <a href=\"https:\/\/hudson.org.au\/disease\/inflammation\/covid-19\/\" class=\"flex flex-col md:flex-row\">\n                    <div class=\"w-full md:w-1\/4\">\n                        \n                            <img decoding=\"async\" class=\"block object-cover w-full\" src=\"https:\/\/hudson.org.au\/wp-content\/uploads\/2020\/10\/coronavirus-2square-440x375.jpg\">\n                                            <\/div>\n                    <div class=\"flex flex-col justify-center w-full md:w-3\/4 p-4 xl:p-8\">\n                        <p class=\"uppercase font-black text-pink-500 text-base sm:text-lg mb-0\">Diseases we research<\/p>\n                        <p class=\"text-blue-700 hover:text-pink-500 text-xl sm:text-2xl xl:text-3xl font-bold\">\n                            <span class=\"inline\">COVID-19 | Learn more<\/span>\n                            <svg class=\"inline ml-1 h-4 sm:h-6 align-center text-pink-500 fill-current\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"15 0 24 34.78\">\n                                <polygon points=\"19.17 34.78 16.27 31.66 31.63 17.39 16.27 3.11 19.17 0 37.87 17.39 19.17 34.78\"><\/polygon>\n                            <\/svg>\n                        <\/p>\n                    <\/div>\n                <\/a>\n            <\/div>\n        \n\n\n<p><strong>Funders |<\/strong>&nbsp;Victorian Government COVID-19 Treatments Medical Research Fund, NHMRC, The Kenyon Foundation<\/p>\n\n\n\n<p><strong>Collaborators |<\/strong>\u00a0<a href=\"https:\/\/www.monash.edu\/discovery-institute\/de-nardo-lab\/home\" target=\"_blank\" rel=\"noreferrer noopener\">Monash University<\/a>, <a href=\"https:\/\/www.centenary.org.au\/research\/programs\/centenary-uts-centre-for-inflammation\/\" target=\"_blank\" rel=\"noreferrer noopener\">UTS and Centenary Institute<\/a>, ANU, St. Vincent\u2019s Institute of Medical Research, UNSW, University of Adelaide, Francis Crick Institute and <a href=\"https:\/\/www.noxopharm.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Noxopharm Limited<\/a>.<\/p>\n\n\n\n<p><strong>Journal information |<\/strong>\u00a0<a href=\"https:\/\/www.nature.com\/articles\/s41467-023-41381-9#auth-Tomalika_R_-Ullah-Aff1-Aff2\" target=\"_blank\" rel=\"noreferrer noopener\">Tomalika R. Ullah<\/a>,\u00a0<a href=\"https:\/\/www.nature.com\/articles\/s41467-023-41381-9#auth-Michael_P_-Gantier-Aff1-Aff2\" target=\"_blank\" rel=\"noreferrer noopener\">Michael P. Gantier<\/a>, et al\u00a0(2023) Pharmacological inhibition of TBK1\/IKK\u03b5 blunts immunopathology in a murine model of SARS-CoV-2 infection <em>Nature Communications <\/em><a href=\"https:\/\/www.nature.com\/articles\/s41467-023-41381-9\" target=\"_blank\" rel=\"noreferrer noopener\">DOI:10.1038\/s41467-023-41381-9<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-contact-us\"><strong>Contact us<\/strong><\/h3>\n\n\n\n<p>Hudson Institute communications |&nbsp;<strong>t:&nbsp;<\/strong>+ 61 3 8572 2761 |&nbsp;<strong>e:<\/strong>&nbsp;<a href=\"mailto:communications@hudson.org.au\">communications@hudson.org.au<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A cancer drug could play an important role in limiting the damaging effects of lung disease inflammation in COVID-19 patients, thanks to new research at Hudson Institute.&hellip;&nbsp;&nbsp;<a class=\"read-more\" href=\"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/\">Read more<\/a><\/p>\n","protected":false},"featured_media":58441,"menu_order":0,"template":"","issue":[],"tag":[],"story-type":[85],"treatment-type":[],"class_list":["post-58427","hdsn_news_post","type-hdsn_news_post","status-publish","has-post-thumbnail","hentry","story-type-discovery"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer drug limits COVID inflammation | Hudson Institute<\/title>\n<meta name=\"description\" content=\"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer drug limits COVID inflammation\" \/>\n<meta property=\"og:description\" content=\"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/\" \/>\n<meta property=\"og:site_name\" content=\"Hudson Institute of Medical Research\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-26T01:53:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/\",\"name\":\"Cancer drug limits COVID inflammation | Hudson Institute\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Michael-Gantier-idronoxil-covid-2.jpg\",\"datePublished\":\"2023-09-19T03:22:20+00:00\",\"dateModified\":\"2023-09-26T01:53:41+00:00\",\"description\":\"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/#primaryimage\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Michael-Gantier-idronoxil-covid-2.jpg\",\"contentUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Michael-Gantier-idronoxil-covid-2.jpg\",\"width\":600,\"height\":600,\"caption\":\"Associate Professor Michael Gantier researching Covid-19 at Hudson Institute\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hudson.org.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cancer drug limits COVID inflammation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#website\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/\",\"name\":\"Hudson Institute of Medical Research\",\"description\":\"Transforming lives through scientific discovery.\",\"publisher\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hudson.org.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-AU\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#organization\",\"name\":\"Hudson Institute of Medical Research\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/hudson-logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/hudson-logo-1.jpg\",\"width\":1200,\"height\":316,\"caption\":\"Hudson Institute of Medical Research\"},\"image\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer drug limits COVID inflammation | Hudson Institute","description":"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/","og_locale":"en_US","og_type":"article","og_title":"Cancer drug limits COVID inflammation","og_description":"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.","og_url":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/","og_site_name":"Hudson Institute of Medical Research","article_modified_time":"2023-09-26T01:53:41+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/","url":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/","name":"Cancer drug limits COVID inflammation | Hudson Institute","isPartOf":{"@id":"https:\/\/hudson.org.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/#primaryimage"},"image":{"@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/#primaryimage"},"thumbnailUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg","datePublished":"2023-09-19T03:22:20+00:00","dateModified":"2023-09-26T01:53:41+00:00","description":"Cancer drug could be used to treat damaging inflammation in severe COVID-19 infections - the remedy desperately needed during the pandemic.","breadcrumb":{"@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/"]}]},{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/#primaryimage","url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg","contentUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2023\/09\/Michael-Gantier-idronoxil-covid-2.jpg","width":600,"height":600,"caption":"Associate Professor Michael Gantier researching Covid-19 at Hudson Institute"},{"@type":"BreadcrumbList","@id":"https:\/\/hudson.org.au\/news\/cancer-drug-protects-against-excessive-inflammation-in-covid-infections\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hudson.org.au\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/hudson.org.au\/news\/"},{"@type":"ListItem","position":3,"name":"Cancer drug limits COVID inflammation"}]},{"@type":"WebSite","@id":"https:\/\/hudson.org.au\/#website","url":"https:\/\/hudson.org.au\/","name":"Hudson Institute of Medical Research","description":"Transforming lives through scientific discovery.","publisher":{"@id":"https:\/\/hudson.org.au\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hudson.org.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-AU"},{"@type":"Organization","@id":"https:\/\/hudson.org.au\/#organization","name":"Hudson Institute of Medical Research","url":"https:\/\/hudson.org.au\/","logo":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hudson.org.au\/#\/schema\/logo\/image\/","url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2017\/05\/hudson-logo-1.jpg","contentUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2017\/05\/hudson-logo-1.jpg","width":1200,"height":316,"caption":"Hudson Institute of Medical Research"},"image":{"@id":"https:\/\/hudson.org.au\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post\/58427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post"}],"about":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/types\/hdsn_news_post"}],"version-history":[{"count":0,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post\/58427\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/media\/58441"}],"wp:attachment":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/media?parent=58427"}],"wp:term":[{"taxonomy":"issue","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/issue?post=58427"},{"taxonomy":"tag","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/tag?post=58427"},{"taxonomy":"story-type","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/story-type?post=58427"},{"taxonomy":"treatment-type","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/treatment-type?post=58427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}